Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris

Vitiligo Vulgaris Clinical Trial

Official title:
Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris

Status Completed

Clinical Trial Summary

Patients with vitiligo vulgaris are treated with Pimecrolimus twice a day during 6 months. After a baseline visit, patient returns for a control visit after 3 and 6 months of treatment. One reference lesion is clinically evaluated with pictures.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00372307
Study type	Interventional
Source	University Hospital, Ghent
Contact
Status	Completed
Phase	Phase 2
Start date	May 2004
Completion date	November 2004

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00907062` - Ginkgo Biloba for the Treatment of Vitiligo Vulgaris in Adolescents	Phase 1
Completed	`NCT01401374` - Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo	N/A
Not yet recruiting	`NCT03234673` - The Effect of Fractional Co2 Laser Either With Tacrolimus, Calcipotriol or NB-UVB in Stable Generalized Vitiligo	Phase 1
Completed	`NCT01206374` - Questionnaire and Laboratory Data on Vitiligo Vulgaris	N/A